Population-based active surveillance of pertussis hospitalization rates in two cities of China
Authors:
Open Access
- 9 December 2024
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 44 (2) , 355-364
Abstract
Purpose Hospitalization is most common for severe pertussis cases and those with serious complications caused by pertussis. In mainland China, the immunization program consists of primary vaccinations at 3, 4, and 5 months, followed by a booster at 18 months with DTaP. It remains uncertain whether the first dose at 3 months, rather than 6 weeks as WHO recommended, may increase disease burden, as delayed immunization may lead to lagged protection. This study aimed to determine pertussis hospitalization rates by active surveillance in China, shedding light on immunization strategies for better disease control. Methods From June 1, 2021, to May 31, 2022, two Chinese cities underwent a population-based active surveillance. Suspected pertussis cases were confirmed as pertussis cases through PCR and culture. Pertussis hospitalization rates were calculated by dividing the number of laboratory confirmed pertussis cases by the hospitalization coverage rate of surveillance hospitals and the resident population. Results During the study period 2021–2022, pertussis hospitalization rate in Yiwu was 2.50/100,000 (95% CrI 2.48–2.53), while in Yongcheng, it was 7.90/100,000 (95% CrI 7.81-8.00). In both cities, infants aged < 1 year had the highest hospitalization rate (215.64/100,000: Yiwu; 217.65/100,000: Yongcheng), followed by the age group of 4–5 years (16.37/100,000: Yiwu; 65.70/100,000: Yongcheng). Conclusions This study revealed significant pertussis hospitalization rates in China, particularly among infants aged < 1 year, highlighting the need of timely and early immunization. The higher hospitalization rates in the 4-5-year age group emphasize the importance of targeted preventive measures for preschool children to mitigate the impact of pertussis.Keywords
Funding Information
- the National Science Foundation of China (No. 81973106)
- Sanofi (No. PER00082)
- Operation of Public Health Emergency Response Mechanisms - Infectious Disease Control (102393220020020000029)
- Enhancement of Infectious Disease Surveillance and Control Technological Capabilities (102393240020020000003)
This publication has 19 references indexed in Scilit:
- Increased susceptibility to pertussis in adults at childbearing age as determined by comparative seroprevalence study, China 2010–2016Journal of Infection, 2019
- Severe Pertussis Infections in the United States, 2011–2015Clinical Infectious Diseases, 2018
- The Epidemiology of Nationally Reported Pertussis in the United States, 2000–2016Clinical Infectious Diseases, 2018
- Seroepidemiology of diphtheria and pertussis in Chongqing, China: serology-based evidence of Bordetella pertussis infectionPublic Health, 2018
- Age-specific effectiveness following each dose of acellular pertussis vaccine among infants and children in New ZealandVaccine, 2017
- Pertussis vaccines: WHO position paper, August 2015—RecommendationsVaccine, 2016
- The pertussis enigma: reconciling epidemiology, immunology and evolutionProceedings Of The Royal Society B-Biological Sciences, 2016
- Seroepidemiology of diphtheria and pertussis in Beijing, China: A cross-sectional studyHuman Vaccines & Immunotherapeutics, 2015
- Epidemiological features of pertussis resurgence based on community populations with high vaccination coverage in ChinaEpidemiology and Infection, 2014
- Impact of Acellular Pertussis Preschool Booster Vaccination on Disease Burden of Pertussis in The NetherlandsThe Pediatric Infectious Disease Journal, 2008